Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yon Chong

Psychiatry Omaha, NE Medical Doctor

NPI 1487909453 CMS profile 22263

601 North 30Th St, Creighton University-Department Of Psychiatry, Omaha, NE 68131

Open in the dashboard

General payments

$59,083

368 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yon Chong of Omaha, NE is reported in the CMS Open Payments database as having received $59,083 across 368 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $53,079 63
2024 General $448 20
2023 General $440 16
2022 General $109 1
2021 General $1,576 81
2020 General $1,855 91
2019 General $1,576 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yon Chong
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Yon Chong were reported at $53,079. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Yon Chong Psychiatry median Middle half National median
2019 $1,576 $184 $59–$605 $163
2020 $1,855 $119 $36–$372 $114
2021 $1,576 $143 $43–$576 $132
2022 $109 $153 $50–$590 $149
2023 $440 $170 $56–$651 $160
2024 $448 $179 $57–$673 $164
2025 $53,079 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $54,031 101 payments
  2. Sunovion Pharmaceuticals Inc. $1,769 87 payments
  3. Alkermes, Inc. $864 37 payments
  4. Janssen Pharmaceuticals, Inc $630 32 payments
  5. Otsuka America Pharmaceutical, Inc. $576 35 payments
  6. ITI, Inc. $348 23 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $213 11 payments
  8. Shire North American Group Inc $153 12 payments
  9. Neurocrine Biosciences, Inc. $141 5 payments
  10. Vanda Pharmaceuticals Inc. $116 10 payments
  11. Other $241 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $49,688 19 payments
  2. Food and Beverage $7,486 332 payments
  3. Travel and Lodging $1,862 16 payments
  4. Education $47 1 payment
Products named General payments · program years 2019–2025
  1. Qelbree Viloxazine Hydrochloride $53,527 83 payments
  2. LATUDA $1,677 85 payments
  3. ARISTADA INITIO $754 36 payments
  4. ARISTADA Cns $754 36 payments
  5. ARISTADA Cns $754 36 payments
  6. ARISTADA Cns $754 36 payments
  7. ARISTADA Cns $754 36 payments
  8. INVEGA SUSTENNA $523 30 payments
  9. SPRAVATO $500 26 payments
  10. QELBREE Psychology $456 17 payments
  11. Other $2,894 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

368 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record